Extending the gap between the first and second doses increased the level of protective antibodies, according to research from the University of Oxford published Monday. The researchers were also able to show for the first time that a booster given more than six months after the second dose induced a strong response and increased activity against variants.
Many governments are grappling with vaccine shortages and questions such as whether to give booster shots to ensure hospitals aren’t overwhelmed this winter. The results may help countries determine whether to stretch their supplies by waiting to give second doses, while showing the way to improve protection — without completely redesigning vaccines — using a third dose. Most nations have recommended a gap of 4 weeks to 12 weeks between Astra vaccines currently.
“This is about preparedness,” Andrew Pollard, lead investigator on the Oxford vaccine trials, said at a press briefing Monday. This data show “we can boost responses giving another dose of the AstraZeneca-Oxford vaccine and that’s really important.”
More research on the duration of immunity from two doses and protection against variants would help determine whether booster doses are really needed, Pollard said.
The study found that antibodies induced after a single dose survived to some extent after one year. Still, after 180 days the levels were half those seen at the 28-day peak. A second dose increased antibody levels between four- and 18-fold by one month after the shot, however. Volunteers in the latest study were drawn from Oxford’s original early and late-stage trials for the vaccine last year.
Immune response of Astra shot boosted by mixing dose schedule with Pfizer jab
A mixed schedule of vaccines where a shot of Pfizer's Covid-19 vaccine is given four weeks after a AstraZeneca shot will produce better immune responses than giving another dose of the AstraZeneca shot, the Oxford study said. In any combination, they produced high concentrations of antibodies against the coronavirus spike protein.
Pfizer, Moderna may offer lasting protection
The vaccines made by Pfizer-BioNTech and Moderna set off a persistent immune reaction in the body that may protect against the coronavirus for years, scientists reported on Monday. The findings add to growing evidence that most people immunized with the mRNA vaccines may not need boosters, so long as the virus and its variants do not evolve much beyond their current forms — which is not guaranteed.
Malaysia unveils $36-bn package as curbs extended
Malaysia unveiled a 150 billion ringgit ($36 billion) package to help people through a nationwide lockdown that was extended for a second time with Covid infections still elevated.
The plan includes a 10 billion ringgit direct fiscal injection and will result in the government disbursing 10 billion ringgit in cash aid to the people by the end of the year, Prime Minister Muhyiddin Yassin said on Monday. Those applying for a six-month moratorium on loan repayments will be given automatic approval, regardless of their income status, he added.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)